Triple-negative breast cancer (TNBC) which lacks estrogen receptor (ER) and progesterone receptor (PR) expression and without human epidermal growth factor receptor 2 (HER2) amplification, accounts for 15–20% of breast cancers [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.